Navigation Links
Oncothyreon's PX-866 PI-3 kinase inhibitor named among Top 10 most promising oncology products for partnering by Windhover
Date:11/16/2009

SEATTLE, Nov. 16 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) (the "Company") today announced that the Company's product candidate PX-866, a PI-3 kinase inhibitor, has been selected by Windhover Information, Inc., as one of the Top 10 most promising oncology projects in development that is available for partnering.

The selection was made by an independent committee assembled by Windhover Information, a leading provider of business information products and services to senior executives in the pharmaceutical, biotechnology and medical device industries. As a selected company, Oncothyreon will present data on PX-866 at Windhover's Therapeutic Area Partnerships conference on November 17-19, 2009, in Boston, MA.

PX-866 is an inhibitor of the PI-3-kinase/PTEN/AKT pathway, an important survival signaling pathway that is activated in many types of human cancer. Oncothyreon is currently conducting a Phase 1 trial of PX-866 in patients with advanced metastatic cancer. Based upon the results seen in this trial to date, including the preliminary data presented at the American Society of Oncology Annual Meeting (ASCO) earlier this year, Oncothyreon has made the decision to move PX-866 into Phase 2 clinical development in the first half of 2010. The Phase 2 development program is currently expected to include two or more trials of PX-866 in combination with chemotherapy or other targeted agents and as a single agent.

"Preliminary results from our ongoing trial of PX-866 have demonstrated that the activity of the target, PI-3 kinase, can be down-regulated at doses well below the maximally tolerated dose identified in the intermittent dosing arm," said Robert L. Kirkman, M.D., President and Chief Executive Officer of Oncothyreon. "As reported at ASCO, we have also had several patients with prolonged stable disease
'/>"/>

SOURCE Oncothyreon Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Data for Oncothyreons PX-12 and PX-866 presented at AACR Annual Meeting
2. Oncothyreon files investigational new drug application for PX-866 oncology compound
3. Oncothyreon initiates Phase 1 trial of PX-866 cancer compound
4. Oncothyreons PX-866 is effective in preclinical model of pulmonary fibrosis
5. EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-2076
6. ImaRx Therapeutics Receives Urokinase Lot Release Approval With Extended Expiration Dating
7. EntreMeds Kinase Inhibitor, ENMD-2076, Presented During AACR Special Session
8. ImaRx Therapeutics Satisfies Abbott Note Obligation Associated With the Acquisition of Urokinase
9. ImaRx Therapeutics Signs Letter of Intent With Microbix Biosystems for the Sale of Urokinase
10. CRELUX and ProQinase establish joint crystal-grade kinase protein and structures platform
11. Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMeds Selective Kinase Inhibitor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... ... July 31, 2015 , ... Ralco is honored to ... the Lyon County Fair to be held August 5-9 in Marshall. The Ralco Enrichment ... meals come from and how agriculture impacts their daily lives. This unique exhibit also ...
(Date:7/30/2015)... 30, 2015   GenoSpace , a leading ... and analysis of genomic and other biomedical data, ... joined the company as Vice President of Sales ... "GenoSpace partners with its ... analyze and explore complex sets of genomic, phenotypic ...
(Date:7/30/2015)... ... , ... The 2015 Market Research Report on the Global Propanol Industry ... Propanol market with a focus on the Chinese situation. Major companies included in the ... Chemical, Sanofi, Royal Dutch Shell, LG Chem and Zhejiang Xinhua Chemical. , The report ...
(Date:7/30/2015)... CA (PRWEB) , ... July 30, 2015 , ... ... successful completion of a field clinical study of its canine osteoarthritis stem cell ... with Aratana Therapeutics (Kansas City, KS) and will be marketed in the US ...
Breaking Biology Technology:Ralco Announces Primary Sponsorship of Ralco Enrichment Center at Lyon County Fair 2GenoSpace Introduces Matthew Fischer as Vice President of Sales and Marketing 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3
... , , , , ... Observe Cytotoxicity (greater than 5 - ,10 % Cell Death) , , ... nontoxic to most cell ,types. If you observe more than 5 - 10 % cell ... ,table below for possible causes. , , ...
... , , ... , , , ... transfected using ,currently available transfection reagents, there are significant differences in ... certain cell ,types, such as HeLa, K-562, and Jurkat, the broad-spectrum ...
... , , , Serial Analysis of Gene Expression ... , a cost-effective outsourcing solution for sequencing of both SAGE and ... Agencourt's , SAGE sequencing service provides our clients with: , ... , Long Phred20 read lengths ...
Cached Biology Technology:Uses and Applications of FuGENE 6 Transfection Reagent 2Uses and Applications of FuGENE 6 Transfection Reagent 3Uses and Applications of X-tremeGENE Q2 Transfection Reagent 2SAGE & LONGSAGE SEQUENCING 2
(Date:7/13/2015)... , July 13, 2015 Synaptics Inc. ... human interface solutions, today announced sampling of ClearPad ... display driver integration (TDDI) product targeting smartphones and ... to combine Synaptics , best-in-class touch controller ... driver technology developed in the company,s Japan Design ...
(Date:7/9/2015)... PLEASANTON, Calif. , July 9, 2015 /PRNewswire/ ... tools, today announcing its acquisition of Avid Nano. ... dynamic light scattering (DLS) systems.    ... world,s smallest, fastest and easiest to use protein ... system that measures a protein,s hydrodynamic size, size ...
(Date:7/8/2015)... , July 8, 2015  Trovagene, Inc. (NASDAQ: ... diagnostics, today announced the launch of a study ... Precision Cancer Monitoring℠ (PCM) technology for predicting response ... or a combination of the novel immunotherapy agents ... a PD-1 inhibitor. The 50-patient study will be ...
Breaking Biology News(10 mins):Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4
... and sleep medicine specialists from two Michigan universities ... innovative quantitative analysis, signal-processing technology and computer algorithms ... of their recent findings is that a new ... fibromyalgia patients from healthy controls. Joseph ...
... Network, Departmental and Workgroup Scanners Recognized by ... the Leading Guide ... 2 /PRNewswire/- Fujitsu Computer Products of,America, Inc., a market ... seven Fujitsu scanners earned the "Editor,s Choice",designation in the ...
... The growing number of dams and other impoundments is ... at which they spread, putting natural lakes at risk, ... at Boulder. The research team combined data on ... boating activity from the Great Lakes region. The ...
Cached Biology News:What a sleep study can reveal about fibromyalgia 2What a sleep study can reveal about fibromyalgia 3Fujitsu Scanners Selected as 'Editor's Choice' in Better Buys for Business 2008 Scan-to-File Guide 2Fujitsu Scanners Selected as 'Editor's Choice' in Better Buys for Business 2008 Scan-to-File Guide 3Biological invasions increasing due to freshwater impoundments, says CU-Boulder study 2Biological invasions increasing due to freshwater impoundments, says CU-Boulder study 3
Request Info...
...
Request Info...
... Antibody Modification Services ,,GenScript offers ... labeling and antibody fragmentation. Labeling antibodies ... for visualization and quantitation of the ... is preferable to use only the ...
Biology Products: